Dapagliflozin
Treatment for Chronic Kidney Disease Due To Diabetes Mellitus Type 2
Typical Dosage: Dapagliflozin 10mg daily
Effectiveness
92%
Safety Score
65%
Clinical Trials
1
Participants
150K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Dapagliflozin 10mg daily
Time to Effect
3-6 months for sustained renal benefits
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
20(Treat 20 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
20(Treat 20 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$7,200
Monitoring:$1,200
Side Effect Mgmt:$150
Total Annual:$8,550
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$45,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$10,687.5
Comparison vs ACE inhibitor/ARB alone
Cost Difference
+$7,200/year
More expensive
QALY Difference
+0.70 QALYs
Better outcomes
Dominance
No dominance
Dapagliflozin Outcomes
for Chronic Kidney Disease Due To Diabetes Mellitus Type 2
Efficacy Outcomes
Overall Effectiveness
+92%
Response Rate
+80%
Common Side Effects
Genital mycotic infections
+8%
Urinary tract infections
+5%
Volume depletion/hypotension
+3%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
1 completed trial for Dapagliflozin in Chronic Kidney Disease Due To Diabetes Mellitus Type 2
Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.
NCT06374043COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Almelo, Netherlands +1 more
Started: May 11, 2021